Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15443472 | 1.00 | BACE1 (0.53) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL16837829 | 0.85 | BACE1 (0.52) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL15447479 | 0.81 | BACE1 (0.48) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL18563600 | 0.81 | BACE1 (0.48) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL16837671 | 0.79 | BACE1 (0.46) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL15447304 | 0.77 | BACE1 (0.49) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL29688067 | 0.77 | PABPC1 (0.39) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL23093847 | 0.77 | PABPC1 (0.39) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| Isopropylamine SCHEMBL20480684 | 0.76 | BACE1 (0.56) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL20559366 | 0.75 | NCF1 (0.48) | BACE1HTTCYP1A2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, METTL16, TPMT | BACE1 2246/4885HTT 487/4885CYP1A2 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.